Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury
Kidney International · 2024-10 · 106 (4) · 597-610
DOI: 10.1016/j.kint.2024.06.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2024-10. Verfasst von Yoshio Funahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Acute Kidney Injury, Dexamethasone, Kidney Tubules, Proximal, Epithelial Cells. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NHLBI NIH HHS, US Department of Defense.
Abstract (Originalsprache)
Acute kidney injury (AKI) increases the risk of in-hospital death, adds to expense of care, and risk of early chronic kidney disease. AKI often follows an acute event such that timely treatment could ameliorate AKI and potentially reduce the risk of additional disease. Despite therapeutic success of dexamethasone in animal models, clinical trials have not demonstrated broad success. To improve the safety and efficacy of dexamethasone for AKI, we developed and characterized a novel, kidney-specific nanoparticle enabling specific within-kidney targeting to proximal tubular epithelial cells provided by the megalin ligand cilastatin. Cilastatin and dexamethasone were complexed to H-Dot nanoparticles, which were constructed from generally recognized as safe components. Cilastatin/Dexamethasone/H-Dot nanotherapeutics were found to be stable at plasma pH and demonstrated salutary release kinetics at urine pH. In vivo, they were specifically biodistributed to the kidney and bladder, with 75% recovery in the urine and with reduced systemic toxicity compared to native dexamethasone. Cilastatin complexation conferred proximal tubular epithelial cell specificity within the kidney in vivo and enabled dexamethasone delivery to the proximal tubular epithelial cell nucleus in vitro. The Cilastatin/Dexamethasone/H-Dot nanotherapeutic improved kidney function and reduced kidney cellular injury when administered to male C57BL/6 mice in two translational models of AKI (rhabdomyolysis and bilateral ischemia reperfusion). Thus, our design-based targeting and therapeutic loading of a kidney-specific nanoparticle resulted in preservation of the efficacy of dexamethasone, combined with reduced off-target disposition and toxic effects. Hence, our study illustrates a potential strategy to target AKI and other diseases of the kidney.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, Oregon, USA.
- Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Biomedical & Nutritional Sciences, University of Massachusetts Lowell, Lowell, Massachusetts, USA.
- Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, Oregon, USA; Operative Care Division, Portland VA Medical Center, Portland, Oregon, USA. Electronic address: hutch…
Förderung
- BLRD VA
- NHLBI NIH HHS
- US Department of Defense
- U.S. Department of Health and Human Services
- US Department of Veterans Affairs
- National Institutes of Health
Zitieren
APA
Funahashi, Y., Park, S. H., Hebert, J. F., Eiwaz, M. B., Munhall, A. C., Groat, T., Zeng, L., Kim, J., Choi, H. S., & Hutchens, M. P. (2024). Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury. Kidney International, 106(4), 597-610. https://doi.org/10.1016/j.kint.2024.06.021
Vancouver
Funahashi Y, Park SH, Hebert JF, Eiwaz MB, Munhall AC, Groat T, et al. Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury. Kidney International. 2024;106(4):597-610. doi:10.1016/j.kint.2024.06.021
BibTeX
@article{Funahashi2024,
author = {Funahashi, Yoshio and Park, Seung Hun and Hebert, Jessica F and Eiwaz, Mahaba B and Munhall, Adam C and Groat, Tahnee and Zeng, Lingxue and Kim, Jonghan and Choi, Hak Soo and Hutchens, Michael P},
title = {Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury},
journal = {Kidney International},
year = {2024},
volume = {106},
number = {4},
pages = {597--610},
doi = {10.1016/j.kint.2024.06.021}
}
EUVIMED